SecBot SecBot

TARS drug pipeline

$78.68
−2.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±26.8%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.

ALK-001 gildeuretinol Updated Aug 31

What to watch

ALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.

Bull case
  • Stargardt disease affects ~36,000 clinically diagnosed patients in the U.S. with zero FDA-approved therapies, representing a large orphan-drug commercial opportunity.
  • Phase 2 TEASE-1 data showed a highly statistically significant 29.5% reduction in atrophic lesion growth (p<0.001) and 87% lower risk of significant low-light vision loss, suggesting strong proof-of-concept.
  • ALK-001 holds FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations, which can accelerate development and provide market exclusivity.
Bear case
  • Topline Phase 3 data is not expected until H2 2029, over three years away, offering no near-term catalyst for the stock.
  • The $450M upfront ($270M cash + $180M stock) plus up to $350M in milestones is expensive for a Phase 3 asset, and the $125M PIPE financing dilutes existing shareholders.
  • Stargardt disease trials are notoriously difficult to read on endpoints; the Phase 2 TEASE-1 trial used an untreated external control arm, not a randomized placebo, raising questions about the data's reliability.

Other drugs in filings and trials

no drug report yet
  • XDEMVY Last: Approval · Jul 24, 2023

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Jul 24, 2023XDEMVYApproval−26.8%−10.6%